Patient Access & Support
Reimbursement & Prior Authorization Services
Companies helping manufacturers and providers navigate payer coverage, submit prior authorizations, manage appeals, and resolve claim denials.
Core vendors
Start here when this category is central to your vendor evaluation.
17 surfaced
Adjacent vendors
Useful to review when you want adjacent capabilities, bundled services, or a broader comparison set.
55 surfaced
No vendors match your search.
Related Articles
Analysis
AI Disruption in Pharma Services: Market Structure Implications
AI will change pharma services economics first by compressing routine administrative labor, not by replacing the full hub, specialty-pharmacy, or patient-services operating model. The strongest current use cases are high-volume PA, BV, document intake, payer-status calls, and workflow triage; the weakest are clinical counseling, rare-disease judgment, CGT coordination, and accountable patient support.
Analysis
AI Hub Operations ROI: What Manufacturers Should Expect
Framework for evaluating AI hub operations ROI in pharma patient support: labor savings, time-to-therapy lift, abandonment reduction, quality risk, and savings pass-through.
Analysis
AI Prior Authorization Platform Comparison: Six Vendors Reshaping PA Automation
Head-to-head analysis of six AI-native prior authorization platforms — Infinitus Systems, Tandem AI, Cohere Health, Coral AI, Neon Health, and SuperDial — spanning voice AI, document AI, and agentic workflow architectures, with implications for CMS-0057-F compliance and pharma manufacturer hub operations.
Comparison
AI Prior Authorization Vendors: Infinitus vs SuperDial vs Neon Health vs Coral AI
Head-to-head comparison of four AI-native prior authorization automation vendors targeting different segments of the pharma patient access workflow. Represents the emerging question of where AI inserts into the PA process: voice-based payer call automation (Infinitus, SuperDial), end-to-end multi-channel workflow orchestration (Neon Health), or pre-submission document AI (Coral AI).
Analysis
CMS-0057-F Vendor Readiness Matrix: Who's Ready for January 2027
CMS-0057-F turns prior authorization interoperability from a policy aspiration into a dated procurement event. The winners are not simply vendors that can say "FHIR" in a sales deck; they are vendors with production payer deployments, coverage across the relevant Da Vinci implementation guides, integration paths into core admin and provider workflows, and enough decisioning logic to improve actual PA cycle time.
Analysis
GLP-1 Services Crunch: Which Pharma Services Vendors Scale to 10M Patients?
Institutional analysis of which pharma services vendors can scale to GLP-1 volumes. Hubs, AI-PA, retail shift, DTC/telehealth, compounding, and the 2027 IRA reset.
Analysis
Payer Landscape Overview: Plan Design, Self-Insured Dynamics & Formulary Strategies
Analysis of the U.S. commercial and government payer landscape as it relates to pharmaceutical services vendor selection. This page provides the demand-side context that shapes hub services, copay assistance, specialty pharmacy, and prior authorization vendor requirements.
Analysis
US Pharma Services Market Sizing and 2025 Update
Directional U.S. pharma services market sizing across specialty pharmacy, prior authorization and reimbursement support, copay programs, market access consulting, data/RWE, and commercial technology, with the 2025 banking-report update folded into one public market map.
Analysis
State Prior Authorization Reform Tracker: Gold Carding, CMS-0057, and Vendor Implications
State prior authorization reform tracker for pharma services vendors, covering gold carding, CMS-0057-F interplay, and vendor implications.
Analysis
Therapeutic Area Specialization Guide: How Hub and SP Workflows Differ by Disease
Therapeutic area specialization is the most common source of false comparability in hub and specialty-pharmacy RFPs. Oncology, rare disease, autoimmune, GLP-1/metabolic, and CGT programs use overlapping vendor categories, but the work is fundamentally different: buy-and-bill versus pharmacy benefit, high-touch case management versus high-volume automation, oral adherence versus chain-of-identity logistics, and biosimilar/formulary defense versus patient finding.